TKNO vs. VNRX, ABIO, ICCC, AWH, CODX, OCX, DMTK, AXDX, ACHV, and AFMD
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), Co-Diagnostics (CODX), OncoCyte (OCX), DermTech (DMTK), Accelerate Diagnostics (AXDX), Achieve Life Sciences (ACHV), and Affimed (AFMD). These companies are all part of the "medical" sector.
VolitionRx (NYSE:VNRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
VolitionRx presently has a consensus price target of $2.50, suggesting a potential upside of 212.50%. Alpha Teknova has a consensus price target of $15.00, suggesting a potential upside of 689.47%. Given VolitionRx's higher probable upside, analysts clearly believe Alpha Teknova is more favorable than VolitionRx.
VolitionRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Alpha Teknova has a net margin of -97.85% compared to Alpha Teknova's net margin of -4,379.67%. Alpha Teknova's return on equity of 0.00% beat VolitionRx's return on equity.
In the previous week, Alpha Teknova had 3 more articles in the media than VolitionRx. MarketBeat recorded 11 mentions for Alpha Teknova and 8 mentions for VolitionRx. Alpha Teknova's average media sentiment score of 0.84 beat VolitionRx's score of 0.51 indicating that VolitionRx is being referred to more favorably in the media.
VolitionRx has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
8.1% of VolitionRx shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 15.4% of VolitionRx shares are held by insiders. Comparatively, 15.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alpha Teknova received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 33.33% of users gave Alpha Teknova an outperform vote while only 30.77% of users gave VolitionRx an outperform vote.
Summary
VolitionRx beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
